Health News Releases

  • Today April 22
January 11, 2022 14:50
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today confirmed the company is positioned for growth in the mid- and long-term with the potential to deliver incremental revenue gr
January 11, 2022 11:50
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire Adaptate Biotherapeutics (“Adaptate”), a UK company focused on developing ant
January 11, 2022 10:10
QUANTA Dialysis Technologies Appoints Meghan Fitzgerald and Leslie Norwalk to Board of Directors
QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making dialysis more accessible with its SC+ hemodialysis system, today announced that Meghan Fi
January 10, 2022 17:30
Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences
Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced further expansion of its differentiated ADC pipeline t
January 07, 2022 13:40
Leman Micro Devices: World-first Clinical Trial Proves Cuffless Mobile Device Sensor and App Measures Blood Pressure With Same Accuracy as Cuff-based Machines
Leman Micro Devices’ e-Checkup system has successfully completed a world-first clinical trial and proven it is the only completely cuffless and calibration-free sensor and app capable of measuring blo
January 06, 2022 14:45
FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) f
January 05, 2022 17:20
Galderma Successfully Completes Acquisition of ALASTIN Skincare®
Galderma, the world’s largest independent dermatology company, announced today that it has received antitrust clearance from the U.S. authorities and has completed the acquisition of ALASTIN Skincare®
January 04, 2022 21:05
ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)
ANANDA Scientific Inc., (a biotech pharma company) today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial eval
January 04, 2022 09:55
Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant
Celltrion Group announced today results for its cocktail therapy candidates including neutralisation data against the Omicron variant (B.1.1.529). The Phase I clinical trial is a randomised, double
December 31, 2021 14:10
LEO Pharma Announces FDA Approval of Adbry™ (tralokinumab) as the First and Only Treatment Specifically Targeting IL-13 for Adults With Moderate-to-Severe Atopic Dermatitis
LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab) for the treatment of moderate-to-severe atop
December 27, 2021 11:40
Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0176 in Prostate Cancer
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the
Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis
December 23, 2021 16:30
Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis
Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II EffisayilTM 1 trial, which showed spesolimab, a first-in-class investi
December 23, 2021 14:30
Xlear Files Legal Response to Government’s Lawsuit
Today, Xlear Inc. filed the company’s response to a Department of Justice lawsuit alleging violations of the Federal Trade Commission Act, among other allegations. The company denied all the Governmen
December 22, 2021 14:40
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response
December 22, 2021 10:30
Covetrus Announces New Structure, Focus and Strength within Europe
Covetrus® (Nasdaq: CVET), a global leader in animal-health technology and services, today announced a new organizational structure within Northern and Central Europe to execute the company’s three-yea
December 21, 2021 17:30
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with e
December 21, 2021 17:10
The Potential of PDE5 Inhibitors, Such as AriBio’s AR1001, the Lead Clinical Candidate for Alzheimer’s Disease, Confirmed in a Recent Independent Study
A recently published research article in Nature Aging by a Cleveland Clinic Genomic Medicine Institute (GMI) research team, led by Feixiong Cheng, Ph.D., entitled “Endophenotype-based in silico networ
December 21, 2021 17:00
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders, today announced that the US F
December 21, 2021 11:05
Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics
Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment
December 20, 2021 15:40
Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and its partner American Regent, Inc., a Daiichi Sankyo Group company, today announced that they have reached settl
December 20, 2021 14:15
TEPMETKO® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations
Merck, a leading science and technology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recomm
December 16, 2021 15:30
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service
December 15, 2021 16:30
PCI Pharma Services Announces the Closing of Its Acquisition of LSNE
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the closing of the previously announced acquisition of Lyophilization Services o
December 15, 2021 13:50
BostonGene and NEC Announce Global Partnership
BostonGene Corporation and NEC Corporation (NEC; TSE: 6701) today announced a strategic global partnership agreement that will enable the companies to offer BostonGene Tumor PortraitTM Tests in key in
December 14, 2021 17:05
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global specialty
25 per page50 per page75 per page100 per page